SCHEMBL4414036

SCHEMBL4414036

O=C(C=Cc1c(O)cc(OCc2ccccc2)cc1OCc1ccccc1)c1cc(OCc2ccccc2)c(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.50
▸ SLC5A1 P13866 1/20 0.48
▸ SLC5A2 P31639 1/20 0.48
▸ PTPN1 P18031 1/20 0.48
▸ TNFRSF1A P19438 3/20 0.47
▸ MAOB P27338 2/20 0.46
▸ CYSLTR2 Q9NS75 1/20 0.45
▸ CYSLTR1 Q9Y271 1/20 0.45
▸ APP P05067 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ THRB P10828 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318918 0.88 ABCG2 (0.65) ABCG2SLC5A1SLC5A2PTPN1MAOB
SCHEMBL4883621 0.88 ABCG2 (0.65) ABCG2SLC5A1SLC5A2PTPN1MAOB
SCHEMBL18526958 0.88 TNFRSF1A (0.53) PTPN1TNFRSF1AMAOBAPP
SCHEMBL17237769 0.84 MAOB (0.67) ABCG2SLC5A1SLC5A2PTPN1TNFRSF1A
SCHEMBL8064391 0.83 PTPN1 (0.56) ABCG2PTPN1TNFRSF1AMAOBAPP
SCHEMBL27630436 0.82 ABCG2 (0.50) ABCG2SLC5A1SLC5A2PTPN1MAOB
SCHEMBL8052936 0.81 PTPN1 (0.57) ABCG2PTPN1TNFRSF1AMAOBAPP
SCHEMBL13117246 0.80 SLC5A1 (0.63) ABCG2SLC5A1SLC5A2TNFRSF1AMAOB
SCHEMBL4414040 0.80 SLC5A1 (0.63) ABCG2SLC5A1SLC5A2TNFRSF1AMAOB
SCHEMBL27650595 0.78 ABCG2 (0.53) ABCG2SLC5A1SLC5A2PTPN1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638554-B2 Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2009-12-29 — — US disclosed
US-7329687-B2 Flavanoid compounds as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2008-02-12 — — US disclosed
US-20060264500-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL (US) 2006-11-23 — — US disclosed
EP-1495014-A2 NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS Sri International (US) 2005-01-12 — — EP disclosed
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2004-02-12 — — US disclosed
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents SRI INTERNATIONAL 2003-12-11 — — US disclosed
WO-2003089423-A2 NOVEL FLAVANOIDS AND CHALCONES AS CHEMOTHERAPEUTIC, CHEMOPREVENTIVE, AND ANTIANGIOGENIC AGENTS SRI INTERNATIONAL (US) 2003-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264500-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, CCNE1, CCNA1 ABCG2 271/4885SLC5A1 1841/4885SLC5A2 3536/4885
US-20040029914-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 ABCG2 257/4885SLC5A1 1010/4885SLC5A2 2623/4885
US-20030229136-A1 Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents FLT1, VEGFA, FLT4 ABCG2 245/4885SLC5A1 1118/4885SLC5A2 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback